drugset

drugset / Trial / NCT01744366

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

NCT01744366 ↗

Phase 3 Completed 285 enrolled Ferring Pharmaceuticals

RandomizedParallel-groupOpen-labelTreatment

Summary

One month degarelix/comparator treatment for prostate cancer in Chinese population

Timeline

Start: 2013-01
Primary completion: 2015-05
Completion: 2015-05

Publications

Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blumle A, Schmucker C, Mayer B, Kunath F. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Degarelix	Other / unclassified	80 mg	—
Comparator	Goserelin	Other / unclassified	3.6 mg	—

Indications